"Silent" diabetes and clinical outcome after treatment with contemporary drug-eluting stents: the BIO-RESORT silent diabetes study

von Birgelen, C. et al. (2018) "Silent" diabetes and clinical outcome after treatment with contemporary drug-eluting stents: the BIO-RESORT silent diabetes study. JACC: Cardiovascular Interventions, 11(5), pp. 448-459. (doi:10.1016/j.jcin.2017.10.038) (PMID:29454724)

[img]
Preview
Text
158219.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

1MB

Abstract

Objectives: This study sought to assess the prevalence and clinical impact of silent diabetes and pre-diabetes in “nondiabetic” percutaneous coronary intervention (PCI) all-comers. Background: Patients with undetected and thus untreated (silent) diabetes may have higher event risks after PCI with contemporary drug-eluting stents (DES). Methods: The BIO-RESORT Silent Diabetes study, performed at Thoraxcentrum Twente, is a substudy of the randomized multicenter BIO-RESORT (BIOdegradable Polymer and DuRable Polymer Drug-eluting Stents in an All COmeRs PopulaTion) trial (NCT01674803). Patients underwent oral glucose tolerance testing (OGTT), and assessment of glycosylated hemoglobin with fasting plasma glucose. Primary endpoint was a composite of cardiac death, target vessel–related myocardial infarction, or target vessel revascularization at 1 year. Results: Of the 988 participants, OGTT detected silent diabetes in 68 (6.9%), pre-diabetes in 133 (13.3%), and normal glucose metabolism in 788 (79.8%). Patients with silent diabetes had higher primary endpoint rates (13.2% vs. 7.6% vs. 4.8%; p < 0.001; silent diabetes vs. normal: hazard ratio: 4.2; 95% confidence interval: 1.9 to 9.2). Differences were driven by myocardial infarction (p < 0.001) which occurred mostly <48 h. Based on glycosylated hemoglobin and fasting plasma glucose, silent diabetes was found in 33 (3.3%) patients, pre-diabetes in 217 (22.0%) patients, and normal glucose metabolism in 738 (74.7%) patients; primary endpoint rates were similar to OGTT-based analyses (12.1% vs. 5.5% vs. 3.1%; p = 0.01). Multivariate analyses demonstrated that abnormal glucose metabolism by either diagnostic approach, present in 330 (33.4%) patients, independently predicted adverse event risk (hazard ratio: 2.2; 95% confidence interval: 1.2 to 4.2). Conclusions: Abnormal glucose metabolism was detected in 1 of 3 “nondiabetic” PCI patients and was independently associated with up to 4-fold higher event risks. Future intervention trials should determine whether meaningful benefits accrue from routine glycemia testing in such patients.

Item Type:Articles
Keywords:DES, HbA(1c), OGTT, PCI, drug-eluting stent, impaired glucose tolerance, oral glucose tolerance testing, percutaneous coronary intervention, silent diabetes.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Sattar, Professor Naveed
Authors: von Birgelen, C., Kok, M. M., Sattar, N., Zocca, P., Doelman, C., Kant, G. D., Löwik, M. M., van der Heijden, L. C., Sen, H., van Houwelingen, K. G., Stoel, M. G., Louwerenburg, J. H. W., Hartmann, M., de Man, F. H.A.F., Linssen, G. C.M., Doggen, C. J.M., and Tandjung, K.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:JACC: Cardiovascular Interventions
Publisher:Elsevier
ISSN:1936-8798
ISSN (Online):1876-7605
Published Online:14 February 2018
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in JACC: Cardiovascular Interventions 11(5): 448-459
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record